STAGE IVA PROSTATE CANCER AJCC V8
Clinical trials for STAGE IVA PROSTATE CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IVA PROSTATE CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IVA PROSTATE CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene test guides prostate cancer treatment: less or more hormone therapy?
Disease control OngoingThis study tests whether adjusting hormone therapy based on a patient's genetic risk score can improve outcomes for high-risk prostate cancer. For those with a low genetic risk, a shorter course of hormone therapy (12 months instead of 24) is compared to standard care. For those …
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 16, 2026 22:37 UTC
-
Immune cells re-engineered to attack Hard-to-Treat prostate cancer
Disease control OngoingThis early-phase trial tests a new treatment for men with advanced prostate cancer that no longer responds to hormone therapy. The treatment uses the patient's own immune cells, modified in a lab to recognize and attack cancer cells. The main goals are to find the safest dose and…
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC
-
New combo therapy targets Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in adults with advanced prostate, bladder, or kidney cancer that has spread. The goal is to find the safest dose and see if the combination can help control the disease. About 65 particip…
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC
-
Shorter radiation blasts may be safer and just as effective for prostate cancer
Disease control OngoingThis study tests whether a shorter, higher-dose radiation schedule (hypofractionated) works as well as the standard longer course for men with prostate cancer who have had their prostate removed. About 186 men will be randomly assigned to one of the two radiation plans. The main …
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New combo therapy targets advanced cancers in early trial
Disease control OngoingThis study tests the safety and effectiveness of combining the immunotherapy drug avelumab with other treatments (utomilumab, anti-OX40 antibody, and radiation) in 173 adults with advanced solid tumors that have spread. The goal is to find the best doses and see if these combinat…
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 12, 2026 12:06 UTC
-
Prostate cancer patients may get a break from hormone shots
Disease control OngoingThis study looks at whether men whose metastatic prostate cancer has responded very well to hormone therapy can safely pause treatment. About 79 men will stop their medications under doctor guidance to see if their testosterone levels recover and they remain cancer-free for at le…
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 10, 2026 13:27 UTC
-
New drug cocktail aims to stall advanced prostate cancer in Early-Stage patients
Disease control OngoingThis study tests a combination of three drugs (abiraterone, prednisone, and apalutamide) in 60 men whose prostate cancer has spread but who have not yet received hormone therapy. The goal is to see how long patients can stay on treatment and to measure cancer progression and side…
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 01, 2026 18:06 UTC
-
New drug cocktail shows promise in slowing tough prostate cancer
Disease control OngoingThis study tests whether adding rucaparib to standard enzalutamide treatment helps men with advanced prostate cancer that has spread and stopped responding to hormone therapy. About 61 participants will receive either the combination or enzalutamide alone. The goal is to see if t…
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
Fasting during radiation may ease treatment side effects
Symptom relief OngoingThis study compares time-restricted eating (intermittent fasting) with standard nutritional counseling in 49 adults with prostate, cervical, or rectal cancer receiving radiation or chemoradiation. The goal is to see if fasting reduces treatment side effects and improves how well …
Matched conditions: STAGE IVA PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Jun 16, 2026 12:55 UTC